Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Sep
16
Today In Oncology
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC
New Executive Director of the Duke Cancer Institute Named
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo